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VSV recombinants containing the overlapping L-domain sequences from Ebola virus VP40 (PTAPPEY) were recovered by reverse-
genetics. Replication kinetics of M40-WT, M40-P24L, and M40-Y30A were indistinguishable from VSV-WT in BHK-21 cells, whereas the
double mutant (M40-P2728A) was defective in budding. Insertion of the Ebola L-domain region into VSV M protein was sufficient to alter
the dependence on host proteins for efficient budding. Indeed, M40 recombinants containing a functional PTAP motif specifically
incorporated endogenous tsg101 into budding virions and were dependent on tsg101 expression for efficient budding. Thus, VSV represents
an excellent negative-sense RNA virus model for elucidating the functional aspects and diverse host interactions associated with the L-
domains of Ebola virus.
D 2005 Elsevier Inc. All rights reserved.Keywords: Ebola virus; L-domains; VSV recombinantsIntroduction
The VP40 protein of Ebola virus plays a key role in
driving assembly and budding of virions. Indeed, VP40 will
bud from mammalian cells in the form of a virus-like
particle (VLP) in the absence of other viral proteins (Harty
et al., 2000; Jasenosky and Kawaoka, 2004; Kolesnikova et
al., 2002; Licata et al., 2003; Martin-Serrano et al., 2001;
Noda et al., 2002; Panchal et al., 2003; Timmins et al.,
2001). However, budding of VP40-containing VLPs, as
well as VLPs of other negative-sense RNA viruses, is most
efficient in the presence of additional viral proteins
including GP and NP (Licata et al., 2004; Noda et al.,
2002; Schmitt and Lamb, 2004; Schmitt et al., 2002;
Swenson et al., 2004). In addition to viral proteins, host
proteins such as tsg101 and other components of the ESCRT
machinery have been shown to play an important role in
facilitating efficient release of VP40 VLPs (Irie et al.,
2004b; Licata et al., 2003; Martin-Serrano et al., 2001;0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.03.027
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E-mail address: rharty@vet.upenn.edu (R.N. Harty).Timmins et al., 2003; von Schwedler et al., 2003). Host
proteins contribute to the budding process through inter-
actions with viral late (L) domains present in matrix or
matrix-like proteins (Gottwein et al., 2003; Harty et al.,
2001; Martin-Serrano et al., 2003; Ott et al., 2002; Perez et
al., 2003; Puffer et al., 1997; Strack et al., 2003; von
Schwedler et al., 2003). The VP40 protein is unique in that
it possesses two overlapping L-domain motifs at its N-
terminus. Both the PTAP and PPEY motifs of VP40 have
been shown to possess L-domain activity in a VLP budding
assay and mediate interactions with host proteins tsg101 and
Nedd4, respectively (Harty et al., 2000; Licata et al., 2003;
Timmins et al., 2003). The use of VP40 VLP budding
assays has provided much useful information regarding the
importance of the L-domain region to budding. However, to
more accurately assess the role of the Ebola virus L-domain
region during virus replication, we attempted to incorporate
the L-domain region of VP40 including flanking amino
acids into VSV using reverse-genetics. Our results indicate
that the VP40 sequences possess L-domain activity in the
context of the VSV M protein and a VSV infection. Each of
the PTAP and PPEY motifs exhibited L-domain activity05) 291 – 298
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packaging specific host proteins. For example, the presence
of the Ebola virus PTAP motif altered the dependence of
VSVon tsg101 expression for efficient budding. Thus, VSV
represents an excellent model system for characterizing
Ebola virus L-domain function and to elucidate the different
pathways of budding directed by viral L-domains and host
protein interactions.Fig. 1. Growth kinetics of M40 recombinant viruses. (A) Diagram of VSV
genome with the M gene highlighted in grey. The VSV M gene (aa 1–229)
is expanded and the sequences aa 20–31 and aa 33–44 are indicated. The
dotted line indicates that the WT M sequence is maintained. The amino acid
sequence within the L-domain region (20–31) is shown for VSV-WT, PY >
A4 mutant, M40, M40-P24L, M40-P2728A, and M40-Y30A. (B) Graph of
growth kinetics and titers of VSV-WT and PY > A4 at the indicated times
post-infection of BHK-21 cells. The titers represent an average of at least 2
independent experiments. (C) Graph of growth kinetics and titers for M40,
M40-P24L, M40-Y30A, and M40-P2728A at the indicated times post-
infection of BHK-21 cells. The titers represent an average of at least 2
independent experiments.Results
Recovery and growth kinetics of M40 recombinants
To address the function of Ebola virus L-domains and
flanking sequences in the context of a virus infection, VSV
recombinants containing Ebola virus L-domain sequences
were recovered using a reverse-genetics approach (Fig. 1A).
The M40-WT recombinant virus contains amino acids 6–20
from the N-terminus of the VP40 protein of Ebola virus
(Zaire). In addition, three M40 mutants were recovered that
possess mutations in either the 24PTAP27 motif (M40-
P24L), the 27PPEY30 motif (M40-Y30A), or both motifs
(M40-P2728A) (Fig. 1A). The corresponding sequences
within the M protein of VSV-WT and the VSV PY > A4
mutant are shown for comparison (Fig. 1A). The PSAP
region of VSV M (aa 33–44) remained unaltered in all
recombinants, since we demonstrated previously that the
PSAP motif does not have L-domain activity in BHK-21
cells (Fig. 1A) (Irie et al., 2004a).
Growth kinetics for all of the M40 recombinants were
assessed by a one-step growth curve in BHK-21 cells (Fig.
1B). VSV-WT and the budding-defective PY > A4 mutant
served as a positive and negative control, respectively (Fig.
1B). Our results indicated that the growth curves for M40-
WT, M40-P24L, and M40-Y30A were virtually indistin-
guishable from that of VSV-WT (Fig. 1B). Thus, mutations
that disrupted the PTAP motif alone or the PPEY motif
alone did not result in a budding-defective virus in BHK-21
cells. This finding indicates that each Ebola virus L-domain
motif possesses independent L-domain activity in the
context of a VSV infection. In contrast, the M40-P2728A
double mutant was defective in budding as demonstrated by
titers at least 10-fold lower than those of M40-WT at various
time points post-infection (Fig. 1B). Thus, titers of the
budding-defective PY > A4 mutant resembled those of the
L-domain-defective M40-P2728A mutant (Fig. 1B).
We next examined the virion protein profile, plaque area,
and budding using electron microscopy for the M40
recombinants. The protein profiles of VSV-WT, PY>A4,
M40-WT, M40-P24L, M40-Y30A, and M40-P2728A viri-
ons were compared by SDS–PAGE (Fig. 2A). As expected,
the amount of virion proteins detected for the budding-
defective PY > A4 mutant was reduced significantly from
that of VSV-WT (Fig. 2A, lanes 1 and 2). Similarly, the
amount of virion proteins detected for M40-P2728A wasreduced significantly from that of M40-WT (compare lanes
3 and 6). The amount of virion proteins for the single
mutants M40-P24L and M40-Y30A was virtually identical
to that of M40-WT (compare lanes 3, 4, and 5). These
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PY > A4 and M40-P2728A in Fig. 1. Importantly, the
amount of M protein synthesized from all VSV recombi-
nants was identical in infected cell extracts (Fig. 2B). Thus,insertion of Ebola virus sequences into M did not affect
protein synthesis or stability.
We next sought to determine whether the presence of the
Ebola virus L-domain sequences in VSV M protein affected
plaque size. The plaque areas formed by VSV-WT, PY >
A4, and all of the M40 recombinant viruses on a monolayer
of BHK-21 cells were measured (Fig. 2C). As shown
previously, the plaque size of PY > A4 was approximately
2-fold smaller than that of VSV-WT (Fig. 2C) (Irie et al.,
2004a; Jayakar et al., 2000). No significant difference was
observed between the plaque size formed by VSV-WT and
that formed by M40-WT (Fig. 2C). Similarly, average
plaque areas formed by M40-P24L and M40-Y30A were
indistinguishable from those of M40-WT, whereas M40-
P2728A displayed a small-plaque phenotype similar to that
of PY > A4 (Fig. 2C).
We next utilized electron microscopy to visualize
budding virions. We predicted that the double mutant would
display the characteristic membrane-tethered phenotype on
the plasma membrane of infected cells. Indeed, relatively
few budding virions of M40-WT, M40-P24L, and M40-
Y30A were found tethered to the plasma membrane,
whereas M40-P2728A was found predominantly tethered
to the surface of the cell (Fig. 2D). Interestingly, M40-WT
virions, and to a slightly lesser degree M40-P24L and M40-
Y30A virions (data not shown), were observed on internal
membranes and in intracellular vesicles (Fig. 2D).
The type of L-domain present directs packaging of host
proteins into budding virions and dictates the pathway for
efficient budding
The packaging of specific host proteins into budding
VP40 VLPs has been reported by us previously (Licata et
al., 2003). Incorporation of specific host proteins in budding
VLPs is thought to be indicative of a biological function for
these host proteins during the budding process. We sought
to determine whether the M40 recombinants possessing
different L-domain motifs would interact with and package
distinct host proteins into infectious virus.
BHK-21 cells were infected with VSV-WT, PY > A4, or
the M40 recombinants, and equivalent amounts of virions
were harvested at 8 h post-infection. Antiserum against
endogenous tsg101 was used to determine whether tsg101Fig. 2. Characterization of VSV recombinants by protein profiles, plaque
area, and electron microscopy. (A) SDS–PAGE analysis of virion proteins
from virions released from BHK-21 cells at 8 h post-infection. The G, N/P,
and M proteins are indicated for VSV-WT (lane 1), PY>A4 (lane 2), M40-
WT (lane 3), M40-P24L (lane 4), M40-Y30A (lane 5), and M40-P2728A
(lane 6). The L protein is not shown. (B) SDS–PAGE analysis of M protein
levels in cells infected with the indicated virus. (C) The relative plaque
areas for VSV-WT, PY > A4, M40-WT, M40-P24L, M40-Y30A, and M40-
P2728A are shown as a bar graph. The average plaque area for VSV-WT
was set at 1.0. The bars represent an average of multiple plaque area
calculations using BHK-21 cells. (D) Representative electron micrographs
of M40-WT- and M40-P2728A-infected BHK-21 cells.
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endogenous tsg101 was not detected at appreciable levels in
VSV-WT virions (Irie et al., 2004a); however, tsg101 was
readily detected in M40-WT virions (Fig. 3A, compare
lanes 1 and 2). Interestingly, tsg101 was also detected in theM40-Y30A recombinant (lane 4), but was not present in the
PTAP-deficient M40-P24A and M40-P2728A recombinants
(Fig. 3A, lanes 3 and 5). Similar results were obtained using
human 293T and HeLa cells (data not shown).
To prove that endogenous tsg101 was indeed packaged
within the virus particles, purified M40-WT virions were
treated with detergent alone, trypsin alone, or detergent plus
trypsin (Fig. 3B). As expected, tsg101 was completely
degraded when virions were treated with both TX-100 and
trypsin (lane 4). In contrast, tsg101 was not degraded in the
presence of trypsin alone (lane 2) or TX-100 alone (lane 3).
The M protein of VSV was used as an internal virion protein
control under identical conditions (Fig. 3B, lanes 5–8).
Thus, endogenous tsg101 is indeed incorporated into
budding virions, and there is a strict correlation between
incorporation of specific host proteins into budding virions
and the type of functional L-domain present in the viral
matrix protein.
Functional role of tsg101 in budding of VSV M40
recombinants
We next sought to determine whether incorporation of
host proteins into budding virions does indeed correlate with
a functional relevance for efficient budding. Toward this
end, expression of endogenous tsg101 in human 293T cells
was inhibited by transfection of siRNAs specific for tsg101.
A non-specific (NS) siRNA was transfected in an identical
manner and served as a negative control. Transfection of
tsg101 siRNA (Fig. 3C, lane 2), but not of NS siRNA (lane
1), was shown to inhibit expression of tsg101 in 293 cells
that were subsequently infected with virus. Identical protein
profiles of total cell extracts from NS-siRNA- and tsg101-
siRNA-transfected cells were observed following staining
with Coomassie blue (Fig. 3C, lanes 3 and 4, respectively).
Human 293T cells were transfected with tsg101 or NS
siRNA twice, followed by infection with the indicated virus
(Fig. 3D). The titer of each virus in the presence of NS
siRNAwas set at 1.0 (Fig. 3D). As expected, titers of VSV-Fig. 3. Packaging of endogenous tsg101 into virions. Western blot using
anti-tsg101 antiserum to detect endogenous tsg101 packaged into VSV-WT
(lane 1), M40-WT (lane 2), M40-P24L (lane 3), M40-Y30A (lane 4), and
M40-P2728A (lane 5) virions released from BHK-21 cells. (B) Protease
protection assay. Purified virions were either untreated (lanes 1 and 5),
treated with trypsin alone (lanes 2 and 6), TX-100 alone (lanes 3 and 7), or
TX-100 and trypsin (lanes 4 and 8). The presence of endogenous tsg101
(lanes 1–4) or VSV M (lanes 5–8) was determined by Western blot. (C)
Western blot demonstrating that endogenous tsg101 expression is inhibited
following transfection of tsg101-siRNA (lane 2), but is not inhibited
following transfection of NS-siRNA (lane 1). Coomassie blue stain of total
protein extract from NS-siRNA-transfected cells (lane 3) and tsg101-
siRNA-transfected cells (lane 4). (D) tsg101 siRNA inhibits budding of
PTAP-containing recombinants. Human 293T cells were first transfected
with tsg101-specific siRNA or a non-specific (NS) siRNA, and then
infected with VSV (wt), M40-WT, M40-P24L, M40-Y30A, or M40-
P2728A. Virion release in the presence of NS siRNA was set at 1.0 for all
viruses. Each white bar represents an average of at least three independent
experiments.
Fig. 4. (A) Human 293T cells were transfected with Nedd4 or AIP4 in the
absence (top panels) or presence (bottom panels) of VP40-WT. VLPs were
floated on a discontinuous sucrose gradient and equivalent fractions from
the top (#1) to bottom (#12) of the gradient were analyzed for the presence
of Nedd4 or AIP4 by Western blotting. As a control, cell lysates (Cell) from
each condition were analyzed similarly to demonstrate expression of Nedd4
and AIP4 in cells. (B) Western blot using anti-Nedd4 antiserum to detect
endogenous Nedd4 packaged into VSV-WT (lane 1), PY > A4 (lane 2),
M40-WT (lane 3), M40-P24L (lane 4), M40-Y30A (lane 5), and M40-
P2728A (lane 6) virions released from BHK-21 cells.
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inhibited (Fig. 3D), indicating that this PPPY-containing
virus is not dependent on tsg101 expression for efficient
budding. In contrast, titers of M40-WT were reduced by
approximately 5.0-fold in the presence of tsg101 siRNA as
compared to those in the presence of NS siRNA (Fig. 3D).
Similarly, titers of M40-Y30Awere reduced by > 5.0-fold in
the presence of tsg101 siRNA compared to those in the
presence of NS siRNA (Fig. 3D). Lastly, titers of both M40-
P24L and M40-P2728A were reduced < 2.0-fold in the
presence of tsg101 siRNA (Fig. 3D). These results
demonstrate that recombinants possessing a functional
PTAP type L-domain were more sensitive to depletion of
tsg101 than those viruses possessing a functional PPxY type
L-domain. Of interest is the finding that M40-WT was
sensitive to depletion of tsg101, although this recombinant
possesses both a PTAP and a PPxY L-domain. These data
indicate that the short L-domain sequence from Ebola virus
is enough to re-direct the budding pathway of infectious
VSV to one that is dependent on tsg101 and presumably
other ESCRT proteins for efficient release.
Packaging of Nedd4 into VP40 VLPs and recombinant
viruses
The PPxY L-domain is known to mediate interactions
with cellular ubiquitin ligases through their WW-domains.
Previous work in our laboratory demonstrated that VP40
could interact in vitro with the yeast Rsp5 protein (Nedd4
homolog), a ubiquitin ligase with multiple WW-domains
(Harty et al., 2000). To demonstrate further that such an
interaction could occur in vivo, we examined the ability of
VP40 to recruit ubiquitin ligases into VLPs. Cells were
transfected with ubiquitin ligases Nedd4 or AIP4 in the
absence (top panels) or presence (bottom panels) of VP40
(Fig. 4A). VLPs were harvested from the culture media by
pelleting through a sucrose cushion and subsequent flotation
on a discontinuous sucrose gradient. Under these conditions,
VP40 VLPs have been shown to partition in upper fractions
2 and 3 (Licata et al., 2004). Neither Nedd4 nor AIP4 was
detected in any VLP fraction in the absence of VP40 (Fig.
4A, top panels). However, in cells co-expressing VP40,
Nedd4 was detected in purified VLPs (Fig. 4A, bottom
panel, lane 2), whereas AIP4 was not. These data indicate
that VP40 can recruit Nedd4 into VLPs and that recruitment
of Nedd4 is specific, as the related family member, AIP4,
was excluded from VP40 VLPs (Fig. 4A, bottom panel,
lane 2).
We next sought to determine whether the M40 recombi-
nants possessing different L-domain motifs would interact
with and package Nedd4 into infectious virus. As described
above for tsg101, BHK-21 cells were infected with VSV-
WT, PY > A4, or the M40 recombinants, and equivalent
amounts of virions were harvested at 8 h post-infection.
Antiserum against endogenous Nedd4 was used to detect
Nedd4 in budding virions (Fig. 4B). Indeed, endogenousNedd4 was detected in VSV-WT (Fig. 4B, lane 1), but was
not detected at an appreciable level in the PY > A4
recombinant (lane 2). Interestingly, Nedd4 was packaged
abundantly in M40-WT (lane 3) and in the M40-P24L
recombinant (lane 4). Both of these viruses possess an intact
PPEY motif. Conversely, the level of Nedd4 packaged into
recombinants M40-Y30A (lane 5) and M40-P2728A (lane
6) was significantly lower than that packaged into M40-WT
and M40-P24L. As described above for tsg101, there is
good correlation between incorporation of endogenous
Nedd4 into budding virions and the type of functional L-
domain present in the viral matrix protein.Discussion
The precise mechanism by which viral L-domains and
host protein interactions mediate efficient budding remains
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assay has revealed much useful information regarding the
molecular aspects of VP40 budding (Irie et al., 2004b;
Kolesnikova et al., 2002; Licata et al., 2003, 2004; Martin-
Serrano et al., 2001; Noda et al., 2002; Swenson et al., 2004;
Timmins et al., 2001, 2003; Yasuda et al., 2003), functional
characterization of these Ebola sequences in the context of a
virus infection is essential, since differences in L-domain
function may exist between a VLP budding assay and a
virus infection. We hypothesized that the VSV model
system would be ideal for studying the L-domain function
of a BSL-4 pathogen such as Ebola virus. For example,
insertion of the Ebola virus L-domain in place of that of
VSV M resulted in a 10- to 12-fold enhancement of VLP
budding (Irie et al., 2004b). In contrast, a similar budding
advantage was not observed in this report when the identical
Ebola virus L-domain was engineered into the VSV genome
to yield the M40-WT recombinant. It is possible that the
M40-WT recombinant may have a budding advantage over
VSV-WT in a cell type other than BHK-21 cells, or perhaps
that the Ebola virus L-domains are not as efficient in the
context of a VSV infection. Interestingly, preliminary data
indicate that the M40-WT recombinant buds from a
mosquito cell line at 100- to 1000-fold higher titers than
VSV-WT (Irie and Harty, unpublished data). It will be of
interest to determine whether this enhancement is due solely
to the insertion of Ebola virus L-domain sequences.
Earlier studies by our group demonstrated that each L-
domain motif within VP40 possesses L-domain activity
alone in a VLP budding assay (Licata et al., 2003). In this
report, we expanded on these findings by demonstrating that
each of the Ebola virus L-domain motifs alone was
functional in the context of a VSV infection. Indeed,
recombinants possessing a mutation in either the PTAP
(M40-P24L) or PPEY (M40-Y30A) motif were able to bud
as well as M40-WT and VSV-WT in BHK-21 cells. In
contrast, the double mutant (M40-P2728A) was defective in
budding due to the lack of L-domain activity. It should be
noted that insertion of the Ebola virus L-domain sequence
into the VSV genome did not adversely affect synthesis of
M protein or virion morphology as determined by immu-
noprecipitation and electron microscopy.
The Ebola virus L-domain sequence not only was able to
function in the context of a VSV infection, but also was able
to redirect budding of VSV into a tsg101-dependent
pathway. Indeed, the presence of the Ebola virus PTAP
motif and flanking amino acids within the VSV M protein
allowed for an interaction with endogenous tsg101 and
packaging of this host protein into budding virions.
Importantly, the PTAP-containing M40 recombinants were
functionally dependent on tsg101 expression for efficient
release as demonstrated by siRNA techniques. Interestingly,
budding of M40-WTwas reduced to a level similar to that of
M40-Y30A in the presence of tsg101 siRNA. This finding
suggests that the Ebola virus PTAP L-domain motif in M40-
WT may be more dominant than the PPEY motif, eventhough the PPEY motif possesses L-domain activity alone
in recombinant M40-P24L. In addition to tsg101, endoge-
nous Nedd4 was found to be packaged specifically into
VP40 VLPs and efficiently into VSV recombinants pos-
sessing an intact PPxY motif. The ability of VSV or VSV
recombinants to utilize other members of the ESCRT
machinery for efficient budding remains to be determined.
Increasing evidence suggests that non-PTAP-containing
retroviruses also utilize the ESCRT machinery for budding
(Demirov and Freed, 2004; Kikonyogo et al., 2001; Martin-
Serrano et al., 2003, 2005; Strack et al., 2003).
It is intriguing that the 15-amino-acid L-domain region of
Ebola virus was sufficient to modify the budding pathway of
VSV from a tsg101-independent pathway to a tsg101-
dependent pathway. Thus, VSV represents a realistic and
valuable model system for comparing and contrasting the
mechanisms by which the various types of L-domains
promote budding. We are in the process of using reverse-
genetics to recover additional VSV recombinants possessing
L-domain regions from various human pathogens, and we
hope to utilize these recombinants to elucidate the role of
both viral and host determinants of budding.Materials and methods
Cells, viruses, and antibodies
BHK-21 and human 293T cells were maintained in
Dulbecco’s minimum essential medium (DMEM; Life
Technologies, Rockville, MD) supplemented with 10% fetal
bovine serum (Life Technologies) and penicillin-streptomy-
cin (Life-Technologies). All VSV recombinants and a
recombinant Vaccinia virus (VvT7) were propagated in
BHK-21 cells. All virus stocks were titrated by standard
plaque assay on BHK-21 cells. Monoclonal antibody (mAb)
23H12 specific for the M protein of VSV (Indiana) was
kindly provided by D.S. Lyles (Wake Forest University,
School of Medicine, Winston-Salem, NC). A plasmid
encoding AIP4 was kindly provided by R. Longnecker
(Northwestern Univ., Illinois). Anti-tsg101 mAb (4A10;
Gene Tex) and anti-Nedd4 pAb (BD PharMingen) were
used according to the protocols of the suppliers.
Construction and recovery of VSV recombinants
Plasmid pVSV-FL encoding full-length VSV cDNA
(Indiana serotype) was kindly provided by J.K. Rose (Yale
University School of Medicine, New Haven, CT). Con-
struction of the chimeric M40 gene was described previ-
ously (Irie et al., 2004b), and mutations were introduced
into the M40 gene using a standard PCR technique to yield
M40-P24L, M40-Y30A, and M40-P2728A genes. These
chimeric genes were inserted back into pVSV-FL to
generate M40-WT, M40-P24L, M40-Y30A, and M40-
P2728A recombinant viruses.
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BHK-21 cells in 6-well plates were infected with VSV
recombinants at an MOI of 10. After 1-h incubation at 37
-C, inocula were removed, cells were washed with
phosphate-buffered saline (PBS) three times, and then
incubated in serum-free DMEM at 37 -C for 8 h. Culture
medium was harvested and clarified at 3000 rpm for 10 min.
Virions were then centrifuged at 36,000 rpm for 2.5 h
through a 20% sucrose cushion. The pellet was suspended in
SDS–PAGE sample buffer (125 mM Tris–HCl [pH 6.8],
4.6% sodium dodecyl sulfate [SDS], 10% 2-mercaptoetha-
nol, 0.005% bromophenol blue, 20% glycerol) and analyzed
by SDS–PAGE (8%) followed by staining with GelCode
Blue Stain Reagent (Pierce). Cell lysates were also prepared
and analyzed by Western blotting using anti-M mAb.
One-step growth curve of VSV recombinants
BHK-21 cells in 6-well plates were infected with VSV
mutants at an MOI of 10. After 1-h incubation at 37 -C,
inocula were removed, cells were washed with 1  PBS
three times, and incubated with DMEM containing 10%
FBS at 37 -C. At the designated time points, culture
medium was harvested and titrated in duplicate by a
standard plaque assay on BHK-21 cells.
Protease treatment of virions
BHK-21 cells in three 35-mm diameter dishes were
infected with M40-WT virus at an MOI of 10. At 10 h p.i.,
the culture medium was harvested and clarified by
centrifugation at 3000 rpm for 10 min. The supernatant
was then centrifuged at 36,000 rpm for 2.5 h through a 20%
sucrose cushion. The virion pellet was suspended into 200
Al of 1  PBS. 50 Al of the suspension was incubated with
trypsin (10 Ag/ml) or PBS in the presence or absence of
0.01% Triton X-100 at 37 -C for 2 h. Samples were then
mixed with 3  SDS–PAGE sample buffer, boiled, and
subjected to SDS–PAGE followed by Western blotting
using antibodies specific for tsg101 or VSV M.
VP40 VLP floatation gradient
Human 293T cells were transfected with plasmids
expressing either c-myc-tagged Nedd4 or flag-tagged
AIP4. At 48 h p.t., culture medium was harvested and
VLPs isolated through a 20% sucrose cushion. Resuspended
VLPs were then floated on a discontinuous sucrose gradient
(80%, 50%, and 10%) by centrifugation at 36,000 rpm for
18 h. Twelve 1-mL fractions were taken from the top to
bottom of the gradient and proteins were isolated by TCA
precipitation and resuspended in 1  Laemmli sample
buffer. Transfected cells were lysed in RIPA buffer (50 mM
Tris [pH 8.0], 150 mM NaCl, 1% NP-40, 0.5% deoxy-
cholate, 0.1% sodium dodecyl sulfate [SDS]). Proteins wereseparated by SDS–PAGE and transferred to nitrocellulose
membranes for Western blotting. Proteins were visualized
by chemiluminescence and autoradiography.
Determination of plaque size
Briefly, BHK-21 cells in 100-mm dishes were infected to
yield approximately 50 plaques per dish. At 24 h p.i., cells
were stained with crystal violet and the area of 10 plaques
on each plate was measured using NIH Image 1.52 software.
Detection of endogenous tsg101 and Nedd4 in virions
Virion samples were prepared as described above. Virion
samples were subjected to SDS–PAGE (8%), followed by
Western blotting using anti-tsg101 mAb and anti-Nedd4
pAb. Virion samples were also applied to SDS–PAGE
(8%), followed by staining by GelCode reagent to confirm
that equivalent amounts of virion proteins were utilized in
this experiment.
siRNA transfection and VSV infection
siRNA transfection and VSV infection were performed
as described previously (Irie et al., 2004b). Briefly, human
293T cells cultured in 6-well plates were transfected with a
combination of 0.2 Ag of tsg101-specific (5V-AAC CTC
CAG TCT TCT CTC GTC-3V) or non-specific (NS) siRNA
(5V-NNA-TTG-TAT-GCG-ATC-GCA-GAC-3V) (Dharmacon
Inc.) using Lipofectamine 2000 (Invitrogen). At 24 h p.t.,
cells were transfected a second time in an identical manner.
After 12 h, cells were infected with VSV at an MOI of 0.01.
At 6 h p.i., culture medium was harvested, and the virus
yield was determined by plaque assay on BHK-21 cells.
Inhibition of tsg101 expression by siRNAwas confirmed by
Western blotting using anti-tsg101 mAb as described
previously (Irie et al., 2004b).Acknowledgments
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